A Phase III clinical trial with 12 sites across Europe was progressing on paper. But the lead CRA was allocated to 3 parallel trials, enrollment pace at 2 sites had dropped 34% below plan, and a document review backlog was growing silently.
Traditional reporting showed “on track” — the underlying data showed an impending 3-month delay. The cost of that delay: €5M in extended site operations, patient retention, and regulatory re-scheduling.
No single system connected the dots between CRA allocation, enrollment pace, and document backlogs. Until Praeveo did.
Resource allocation data showed the lead CRA assigned to 3 concurrent trials with overlapping site visit windows in weeks 14–18.
Two sites showed sustained enrollment decline over 4 consecutive weeks. Pattern consistent with pre-delay trajectory in historical trials.
Regulatory document queue increasing week over week. At current pace, review completion would miss the submission window by 3 weeks.
“The signals were all there — in our data. We just couldn’t see them. Praeveo connected the dots we were missing.”— VP Clinical Operations, Global Pharma Company
30 seconds — and we'll get back to you within 24 hours.
Book a conversation →